Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Parmele

Interventional Pain Medicine Maple Grove, MN Medical Doctor

NPI 1255545687 CMS profile 283594

9645 Grove Cir N Ste 200, Maple Grove, MN 55369

Open in the dashboard

General payments

$12,831

194 records reported · program years 2019–2025

Research payments

$2,645

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$62,713 paid to institutions, not to them · program years 2020–2025

Through program year 2025, James Parmele of Maple Grove, MN is reported in the CMS Open Payments database as having received $12,831 across 194 general payments and $2,645 in research payments paid to them. Separately, studies naming them as principal investigator received $62,713 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 82nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $887 30
2024 General $1,809 36
2023 General $1,370 25
2022 General $1,163 21
2022 Research $2,645 3
2021 General $988 19
2020 General $3,675 32
2019 General $2,939 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Parmele
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to James Parmele were reported at $887. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year James Parmele Interventional Pain Medicine median Middle half National median
2019 $2,939 $684 $216–$2,079 $163
2020 $3,675 $382 $122–$1,109 $114
2021 $988 $552 $167–$1,554 $132
2022 $1,163 $605 $187–$1,924 $149
2023 $1,370 $671 $195–$1,915 $160
2024 $1,809 $684 $206–$1,837 $164
2025 $887 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $5,405 29 payments
  2. Nevro Corp. $2,072 41 payments
  3. Abbott Laboratories $1,419 37 payments
  4. Boston Scientific Corporation $1,392 24 payments
  5. Medtronic, Inc. $809 11 payments
  6. Saluda Medical Americas, Inc. $451 8 payments
  7. BIOTRONIK NRO, Inc. $389 15 payments
  8. Relievant Medsystems, Inc. $266 5 payments
  9. SI-BONE, Inc. $173 3 payments
  10. SPR Therapeutics, Inc $125 1 payment
  11. Other $330 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,266 187 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,750 2 payments
  3. Travel and Lodging $775 4 payments
  4. Education $40 1 payment
Products named General payments · program years 2019–2025
  1. ADAPTIVESTIM $3,750 2 payments
  2. OSTEOCOOL RF ABLATION $956 6 payments
  3. PROCLAIM $715 15 payments
  4. Senza $688 14 payments
  5. INTELLIS ADAPTIVESTIM $659 9 payments
  6. Omnia $645 13 payments
  7. Senza Spinal Cord Stimulation System $559 12 payments
  8. Prospera $389 15 payments
  9. INTELLIS $344 16 payments
  10. WaveWriter Alpha Prime 16 $313 6 payments
  11. Other $3,538 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Nevro Corp. $2,645 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

640

Median for Interventional Pain Management: 1,220

Drug cost

$7,862

Median for Interventional Pain Management: $39,344

Branded share of claims

10.6%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 167 $2,254
Lidocaine Generic 13 $1,144
Tizanidine Hcl Generic 101 $1,031
Topiramate Generic 71 $742
Methocarbamol Generic 34 $520
Baclofen Generic 32 $474
Cyclobenzaprine Hcl Generic 26 $417
Cephalexin Generic 39 $290
Diclofenac Sodium Generic 12 $251
Methylprednisolone Generic 33 $217

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$163,499

Of which drugs: $1,764

Medicare patients

578

Average age 70

Services billed

3,222

388 women, 190 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 65%
Depression 43%
Diabetes 25%
Ischemic heart disease 24%
Chronic kidney disease 22%
Osteoporosis 21%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 40 mg J1030 Office 20 32 $156
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 59 123 $93
Injection, methylprednisolone acetate, 1 mg J1010 Office 12 561 $52
Injection, propofol, 10 mg J2704 Office 25 473 $42
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 70 322 $33
Ringers lactate infusion, up to 1000 cc J7120 Office 11 15 $30

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

197 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record